Research programme: alpha-1 antitrypsin deficiency gene therapy - VIRxSYS

Drug Profile

Research programme: alpha-1 antitrypsin deficiency gene therapy - VIRxSYS

Latest Information Update: 18 Nov 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intronn
  • Developer VIRxSYS Corporation
  • Class Gene therapies
  • Mechanism of Action Trypsin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Alpha 1-antitrypsin deficiency

Most Recent Events

  • 18 Nov 2011 Preclinical trials in Alpha 1-antitrypsin deficiency in USA (Parenteral)
  • 21 Sep 2007 This programme is still in active development
  • 21 Sep 2007 Intronn has been acquired and merged into VIRxSYS Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top